restorative-dentistry-prosthodontics-2017-scientifictracks

Page 44

Notes:

conferenceseries

.com

May 01-02, 2017 Toronto, Canada

International Conference on

Restorative Dentistry and Prosthodontics

Volume 5, Issue 1 (Suppl)

J Oral Hyg Health

ISSN: 2332-0702 JOHH, an open access journal

Restorative Dentistry & Prosthodontics 2017

May 01-02, 2017

Formulation of a chewing gum for treating oral candidiasis

Jones Ozokwere

, Eugene Olivier

, Mulamba Gedeon

and

Patrick Demana

Tshwane University of Technology, South Africa

University of Limpopo, South Africa

ungal infections have become major causes of morbidity and mortality among immuno-compromised patients. Oral candidiasis

is a fungal infection caused the opportunistic pathogen named

Candida albicans

. Conventional available treatments for oral

candidiasis include topical antifungal azoles such as Miconazole, Amphotericin B and Nystatin. Miconazole, in various formulations

(gels, lozenges or mixtures) for local application, is an effective antimycotic drug for treating oral candidiasis. However the increase

of resistant micro-organisms to conventional treatment is becoming a challenge, researchers are trying to identify potential drugs

and alternatives treatments with better and improved therapeutic effects and fewer adverse effects. Essential oils have been used

for the treatment of several diseases. They possess antibacterial, antifungal, antiviral and antiseptic activities. Certain essential oils

have been shown to have antifungal activity or reduce the risk of fungal infections. In this study, a selection of essential oils was

made and evaluated based on their anti-candidal activity, organoleptic properties, availability and minimum inhibitory concentration

for possible inclusion and formulation into the chewing gum as an active pharmaceutical ingredient. Preformulation studies were

conducted to identify suitable excipients and evaluate physicochemical compatibilities of the actives with selected excipients. From

three placebo formulations obtained from the gum base manufacturer, preliminary development of the formulation was done. A

series of formulations were developed by varying different tablet components. The active pharmaceutical ingredients (API’s) were

included in the gum core both at 2% (w/w) of the MCG composition. The formula was subjected to scale-up. Produced MCG’s from

the scale-up were film coated to improve stability. Finished products were subjected to post-compression evaluation including

vitro

release of the API’s from the dosage form. This study proved that it is possible to develop a medicated chewing gum with a

combination of essential oils as active substances for the effective treatment of oral candidiasis.

Jones Ozokwere et al., J Oral Hyg Health 2017, 5:1 (Suppl)